|
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) DCF Valuation
CN | Healthcare | Biotechnology | HKSE
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) Bundle
Discover the true potential of Shanghai Haohai Biological Technology Co., Ltd. (6826HK) with our advanced DCF Calculator! Adjust key assumptions, explore various scenarios, and assess how changes influence the valuation of Shanghai Haohai Biological Technology Co., Ltd. (6826HK) – all within a user-friendly Excel template.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,703.4 | 1,414.0 | 1,868.5 | 2,245.8 | 2,813.2 | 3,239.4 | 3,730.3 | 4,295.5 | 4,946.3 | 5,695.7 |
| Revenue Growth, % | 0 | -16.99 | 32.14 | 20.19 | 25.27 | 15.15 | 15.15 | 15.15 | 15.15 | 15.15 |
| EBITDA | 591.8 | 421.5 | 587.7 | 477.8 | 761.7 | 935.3 | 1,077.0 | 1,240.1 | 1,428.1 | 1,644.4 |
| EBITDA, % | 34.74 | 29.81 | 31.45 | 21.28 | 27.08 | 28.87 | 28.87 | 28.87 | 28.87 | 28.87 |
| Depreciation | 123.2 | 141.9 | 173.9 | 218.0 | 211.2 | 283.7 | 326.7 | 376.2 | 433.2 | 498.8 |
| Depreciation, % | 7.23 | 10.03 | 9.3 | 9.71 | 7.51 | 8.76 | 8.76 | 8.76 | 8.76 | 8.76 |
| EBIT | 468.6 | 279.7 | 413.8 | 259.8 | 550.4 | 651.6 | 750.3 | 864.0 | 994.9 | 1,145.6 |
| EBIT, % | 27.51 | 19.78 | 22.15 | 11.57 | 19.57 | 20.11 | 20.11 | 20.11 | 20.11 | 20.11 |
| Total Cash | 3,440.5 | 3,318.0 | 3,103.9 | 2,713.7 | 2,937.2 | 3,239.4 | 3,730.3 | 4,295.5 | 4,946.3 | 5,695.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 416.4 | 363.8 | 400.6 | 407.3 | .0 | 581.5 | 669.6 | 771.0 | 887.8 | 1,022.4 |
| Account Receivables, % | 24.44 | 25.73 | 21.44 | 18.14 | 0.000015028976 | 17.95 | 17.95 | 17.95 | 17.95 | 17.95 |
| Inventories | 256.2 | 272.4 | 378.8 | 518.1 | 561.8 | 632.4 | 728.2 | 838.6 | 965.7 | 1,112.0 |
| Inventories, % | 15.04 | 19.26 | 20.27 | 23.07 | 19.97 | 19.52 | 19.52 | 19.52 | 19.52 | 19.52 |
| Accounts Payable | 39.3 | 29.9 | 49.4 | 58.2 | 58.8 | 76.1 | 87.7 | 100.9 | 116.2 | 133.8 |
| Accounts Payable, % | 2.31 | 2.12 | 2.64 | 2.59 | 2.09 | 2.35 | 2.35 | 2.35 | 2.35 | 2.35 |
| Capital Expenditure | -426.3 | -209.1 | -290.5 | -338.6 | -285.3 | -522.1 | -601.2 | -692.3 | -797.2 | -917.9 |
| Capital Expenditure, % | -25.03 | -14.79 | -15.55 | -15.08 | -10.14 | -16.12 | -16.12 | -16.12 | -16.12 | -16.12 |
| Tax Rate, % | 18.13 | 18.13 | 18.13 | 18.13 | 18.13 | 18.13 | 18.13 | 18.13 | 18.13 | 18.13 |
| EBITAT | 400.0 | 250.3 | 380.9 | 198.9 | 450.7 | 554.3 | 638.3 | 735.0 | 846.4 | 974.6 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -536.4 | 210.1 | 140.6 | -58.9 | 740.8 | -318.9 | 191.4 | 220.4 | 253.8 | 292.2 |
| WACC, % | 7.54 | 7.55 | 7.55 | 7.52 | 7.53 | 7.54 | 7.54 | 7.54 | 7.54 | 7.54 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 439.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 298 | |||||||||
| Terminal Value | 5,384 | |||||||||
| Present Terminal Value | 3,744 | |||||||||
| Enterprise Value | 4,183 | |||||||||
| Net Debt | -2,490 | |||||||||
| Equity Value | 6,673 | |||||||||
| Diluted Shares Outstanding, MM | 334 | |||||||||
| Equity Value Per Share | 19.96 |
What You Will Receive
- Genuine 6826HK Financial Data: Access to historical and projected figures for precise valuation.
- Customizable Inputs: Adjust metrics such as WACC, tax rates, revenue growth, and capital expenditures.
- Instant Calculations: Dynamic computation of intrinsic value and NPV.
- Scenario Analysis: Explore different scenarios to assess the future performance of Shanghai Haohai Biological Technology Co., Ltd.
- User-Friendly Design: Crafted for industry professionals while remaining approachable for novices.
Key Features
- Customizable Projection Inputs: Adjust essential parameters such as revenue growth, EBITDA margins, and capital expenditures.
- Instant DCF Valuation: Quickly computes intrinsic value, net present value (NPV), and other financial metrics.
- High-Precision Accuracy: Leverages Shanghai Haohai’s actual financial data for realistic valuation results.
- Simplified Scenario Analysis: Effortlessly explore various assumptions and evaluate different outcomes.
- Efficiency Booster: Remove the complexity of constructing detailed valuation models from the ground up.
How It Operates
- Download the Template: Gain immediate access to the Excel-based DCF Calculator for Shanghai Haohai Biological Technology Co., Ltd. (6826HK).
- Input Your Assumptions: Customize the yellow-highlighted cells for growth rates, WACC, profit margins, and other parameters.
- Instant Calculations: The model will automatically refresh to reflect the intrinsic value of Shanghai Haohai Biological Technology Co., Ltd. (6826HK).
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Leverage the results to inform your investment choices or financial assessments.
Why Choose Shanghai Haohai Biological Technology Co., Ltd. (6826HK) Calculator?
- Efficient Use of Time: Skip the hassle of building a DCF model from the ground up – it's set up for immediate use.
- Enhanced Precision: Access to accurate financial data and formulas minimizes valuation errors.
- Completely Adaptable: Customize the model to align with your unique assumptions and forecasts.
- Simple Visualization: User-friendly charts and outputs make it easy to interpret the results.
- Endorsed by Professionals: Crafted for industry experts who prioritize accuracy and functionality.
Who Can Benefit from This Product?
- Investors: Evaluate the valuation of Shanghai Haohai Biological Technology Co., Ltd. (6826HK) before making investment decisions.
- CFOs and Financial Analysts: Enhance valuation methodologies and validate financial forecasts.
- Startup Founders: Understand how established companies like Shanghai Haohai Biological Technology Co., Ltd. (6826HK) are appraised.
- Consultants: Create detailed valuation reports for your clients based on accurate data.
- Students and Educators: Utilize practical data to learn and teach valuation practices effectively.
Contents of the Template
- Operating and Balance Sheet Data: Pre-populated historical data and forecasts for Shanghai Haohai Biological Technology Co., Ltd. (6826HK), including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for the Weighted Average Cost of Capital (WACC), featuring parameters such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Customizable Discounted Cash Flow models presenting intrinsic value alongside comprehensive calculations.
- Financial Statements: Pre-loaded annual and quarterly financial statements to facilitate in-depth analysis.
- Key Ratios: Includes key profitability, leverage, and efficiency ratios specifically for Shanghai Haohai Biological Technology Co., Ltd. (6826HK).
- Dashboard and Charts: Visual representation of valuation outputs and assumptions, enabling straightforward result analysis.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.